作者
Erik B Schelbert, Kayla M Piehler, Karolina M Zareba, James C Moon, Martin Ugander, Daniel R Messroghli, Uma S Valeti, Chung‐Chou H Chang, Sanjeev G Shroff, Javier Diez, Christopher A Miller, Matthias Schmitt, Peter Kellman, Javed Butler, Mihai Gheorghiade, Timothy C Wong
发表日期
2015/12/18
期刊
Journal of the American Heart Association
卷号
4
期号
12
页码范围
e002613
简介
Background
Myocardial fibrosis (MF) in noninfarcted myocardium may be an interstitial disease pathway that confers vulnerability to hospitalization for heart failure, death, or both across the spectrum of heart failure and ejection fraction. Hospitalization for heart failure is an epidemic that is difficult to predict and prevent and requires potential therapeutic targets associated with outcomes.
Method and Results
We quantified MF with cardiovascular magnetic resonance extracellular volume fraction (ECV) measures in 1172 consecutive patients without amyloidosis or hypertrophic or stress cardiomyopathy and assessed associations with outcomes using Cox regression. ECV ranged from 16.6% to 47.8%. Over a median of 1.7 years, 111 patients experienced events after cardiovascular magnetic resonance, 55 had hospitalization for heart failure events, and there were 74 deaths. ECV was more strongly associated with …
引用总数
201620172018201920202021202220232024173824372925203410